Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B
Aim. Hepatitis B virus (HBV) infection is a major public health concern worldwide. Entecavir (ETV), a first-line nucleos(t)ide analogue (NA) for HBV, has a low risk of resistance. We evaluated the efficacy of ETV monotherapy, ratio of ETV-resistant, and the clinical features of patients with ETV res...
Main Authors: | Hideo Takayama, Takuya Komura, Takashi Kagaya, Saiho Sugimoto, Noriaki Orita, Yoshiro Asahina, Masashi Nishikawa, Hajime Ohta, Shuichi Kaneko, Masashi Unoura |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2021/3259833 |
Similar Items
-
Clinical Features and Dynamics of T Cells-Related Markers in Immunocompetent Patients with Cytomegalovirus Hepatitis
by: Takuya Komura, et al.
Published: (2020-01-01) -
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01) -
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
by: Han Na Choi, et al.
Published: (2015-03-01) -
Dynamic changes of HBsAg and hepatitis B virus DNA in chronic hepatitis B patients with entecavir monotherapy for 5 years
by: WU Fengping
Published: (2021-05-01) -
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
by: Dae Won Jun, et al.
Published: (2013-06-01)